(USD M) | Dec'21 | Mar'22 | Jun'22 | Sep'22 | Dec'22 | Mar'23 | Jun'23 | Sep'23 | Dec'23 | Mar'24 | Jun'24 | Sep'24 | Dec'24 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
LTM Revenue % growth | 111.7 40.4% | 121.5 42.3% | 131.6 41.1% | 141.7 38.2% | 150.3 34.6% | 157.2 29.4% | 163.4 24.2% | 168.6 19.0% | 174.5 16.1% | 181.6 15.5% | 188.4 15.3% | 195.2 15.8% | 201.6 15.5% |
LTM NOPAT % growth | (276.5) N/A | (294.5) 6.5% | (304.3) 3.3% | (306.4) 0.7% | (13.0) (95.8%) | 3.8 N/A | 10.0 162.7% | 9.7 (2.9%) | 9.6 (1.0%) | 4.2 (56.0%) | 4.7 11.2% | 4.4 (7.1%) | 3.2 (26.5%) |
Discount rate | 5.7% | 6.7% | 7.5% | 8.1% | 8.3% | 7.9% | 8.2% | 8.9% | 8.1% | 8.5% | 8.6% | 8.0% | 8.8% |
Earnings Power Value (EPV) | (4,825.1) | (4,376.1) | (4,068.2) | (3,764.0) | (157.6) | 48.3 | 122.0 | 109.8 | 118.2 | 50.0 | 54.7 | 54.7 | 36.6 |
Enterprise Value (EV) | 2,545.5 | 1,389.2 | 1,168.4 | 2,167.0 | 1,109.1 | 1,187.4 | 1,314.5 | 1,069.3 | 1,168.9 | 1,124.7 | 1,054.1 | 1,194.0 | 1,318.8 |
Market-Implied Value of Growth (MIVoG) | 7,370.6 | 5,765.3 | 5,236.6 | 5,931.0 | 1,266.7 | 1,139.1 | 1,192.6 | 959.5 | 1,050.7 | 1,074.7 | 999.4 | 1,139.3 | 1,282.2 |
EPV as % of EV | (189.6%) | (315.0%) | (348.2%) | (173.7%) | (14.2%) | 4.1% | 9.3% | 10.3% | 10.1% | 4.4% | 5.2% | 4.6% | 2.8% |
MIVoG as % of EV | 289.6% | 415.0% | 448.2% | 273.7% | 114.2% | 95.9% | 90.7% | 89.7% | 89.9% | 95.6% | 94.8% | 95.4% | 97.2% |
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
As of Dec 31, 2024, Enfusion, Inc.'s Earnings Power Value is approximately $36.6M.
As of Dec 31, 2024, Enfusion, Inc.'s Enterprise Value (EV) estimates at $1,318.8M.
As of Dec 31, 2024, Enfusion, Inc.'s Net operating profit after tax (NOPAT) is approximately $3,218.7K.